• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Neogen Corporation

    6/24/25 3:41:28 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email
    11-K
    0000711377falseFYhttp://www.neogen.com/20241231#FidelityUSBondIndexFundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#FidelityFiveHundredIndexFundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#FidelityMidCapIndexFundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#FidelitySmallCapIndexFundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#FidelityInternationalIndexFundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://www.neogen.com/20241231#FidelityLargeCapGrowthIndexFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#FidelityLargeCapValueIndexFundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#FidelityGovernmentMoneyMarketFundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#LargeCapGrowthIIIR1Memberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2055FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#BlackrockMidCapGrowthEquityPortfolioMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2065FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#TRowePriceBlueChipGrowthFundIClassMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#JPMorganMidCapValueFundClassR6Memberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2020FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2030FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2040FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2050FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#BairdCorePlusBondFundClassInstitutionalMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2070FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardEquityIncomeFundAdmiralSharesMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardExplorerFundAdmiralSharesMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirementIncomeFundInvestorSharesMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2025FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2035FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2045FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardInflationProtectedSecuritiesFundAdmiralSharesMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#PioneerStrategicIncomeFundClassKMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#AmericanFundsEuroPacificGrowthFundClassR-6Memberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#AmericanFundsAmericanBalancedFundClassR-6Memberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#AllspringSpecialSmallCapValueFundClassR6Memberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardTargetRetirement2060FundMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#VanguardSmallCapGrowthIndexFundAdmiralSharesMemberhttp://fasb.org/us-gaap/2024#MutualFundMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://www.neogen.com/20241231#PutnamStableValueFundMemberhttp://fasb.org/us-gaap/2024#DefinedBenefitPlanCommonCollectiveTrustMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanEmployerCommonStockFundMemberhttp://fasb.org/us-gaap/2024#CommonStockMemberhttp://fasb.org/us-gaap-ebp/2024#EmployeeBenefitPlanParticipantDirectedMemberDecember 31, 20290000711377neog:EBP001MemberBaird Core Plus Bond Fund Class Institutional2024-12-310000711377Vanguard Target Retirement 2055 Fundneog:EBP001Member2024-12-310000711377neog:EBP001Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2023-12-310000711377neog:EBP001MemberAmerican Funds American Balanced Fund Class R-62024-01-012024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2065 Fund2024-01-012024-12-310000711377neog:EBP001MemberT. Rowe Price Blue Chip Growth Fund I Class2024-01-012024-12-310000711377neog:EBP001MemberVanguard Equity-Income Fund Admiral Shares2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2045 Fund2024-12-310000711377neog:EBP001MemberVanguard Target Retirement Income Fund Investor Shares2024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2023-12-310000711377Vanguard Target Retirement 2050 Fundneog:EBP001Member2024-01-012024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2025 Fund2024-01-012024-12-310000711377neog:EBP001MemberFidelity International Index Fund2024-01-012024-12-310000711377neog:EBP001MemberVanguard Inflation-Protected Securities Fund Admiral Shares2024-01-012024-12-310000711377neog:EBP001Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-01-012023-12-310000711377neog:EBP001MemberFidelity Large Cap Value Index Fund2024-12-310000711377neog:EBP001MemberAllspring Special Small Cap Value Fund - Class R62024-01-012024-12-310000711377us-gaap-ebp:EmployeeBenefitPlanTrusteeMemberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberus-gaap:MutualFundMember2024-12-310000711377neog:EBP001Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2024-12-310000711377neog:EBP001MemberFidelity Government Money Market Fund2024-01-012024-12-310000711377neog:EBP001MemberFidelity International Index Fund2024-12-310000711377neog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377neog:EBP001MemberLarge Cap Growth III R12024-01-012024-12-310000711377neog:EBP001MemberAllspring Special Small Cap Value Fund - Class R62024-12-310000711377neog:EBP001MemberAmerican Funds EuroPacific Growth Fund Class R-62024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2035 Fund2024-01-012024-12-310000711377neog:EBP001MemberFidelity U.S. Bond Index Fund2024-01-012024-12-310000711377neog:EBP001MemberFidelity Small Cap Index Fund2024-01-012024-12-310000711377JPMorgan Mid Cap Value Fund Class R6neog:EBP001Member2024-01-012024-12-310000711377neog:EBP001Membersrt:MinimumMember2024-01-012024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2030 Fund2024-12-310000711377neog:EBP001MemberBlackrock Mid Cap Growth Equity Portfolio2024-12-310000711377neog:EBP001MemberVanguard Explorer Fund Admiral Shares2024-01-012024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2035 Fund2024-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2023-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMember2023-12-310000711377neog:EBP001Memberus-gaap:MutualFundMember2023-12-310000711377neog:EBP001MemberFidelity 500 Index Fund2024-01-012024-12-310000711377neog:EBP001Member2024-12-310000711377neog:EBP001MemberVanguard Inflation-Protected Securities Fund Admiral Shares2024-12-310000711377neog:EBP001Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-01-012024-12-310000711377neog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2023-12-310000711377neog:EBP001MemberVanguard Target Retirement 2065 Fund2024-12-310000711377neog:EBP001MemberFidelity Mid Cap Index Fund2024-12-310000711377Vanguard Target Retirement 2060 Fundneog:EBP001Member2024-12-310000711377neog:EBP001MemberAmerican Funds American Balanced Fund Class R-62024-12-310000711377neog:EBP001Member2024-01-012024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2025 Fund2024-12-310000711377neog:EBP001MemberCommon Stock— Neogen Corporation2024-12-310000711377us-gaap-ebp:EmployeeBenefitPlanTrusteeMemberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2023-12-310000711377neog:EBP001MemberBaird Core Plus Bond Fund Class Institutional2024-01-012024-12-310000711377neog:EBP001MemberBlackrock Mid Cap Growth Equity Portfolio2024-01-012024-12-310000711377neog:EBP001MemberFidelity Government Money Market Fund2024-12-310000711377neog:EBP001MemberFidelity Mid Cap Index Fund2024-01-012024-12-310000711377neog:EBP001MemberCommon Stock— Neogen Corporation2024-01-012024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Member2024-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberus-gaap:MutualFundMember2024-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377neog:EBP001Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberus-gaap:MutualFundMember2023-12-310000711377neog:EBP001MemberFidelity 500 Index Fund2024-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2024-12-310000711377neog:EBP001MemberVanguard Explorer Fund Admiral Shares2024-12-310000711377neog:EBP001MemberVanguard Target Retirement Income Fund Investor Shares2024-01-012024-12-310000711377us-gaap-ebp:EmployeeBenefitPlanTrusteeMemberneog:EBP001Member2024-01-012024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2045 Fund2024-01-012024-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMember2024-12-310000711377Vanguard Target Retirement 2050 Fundneog:EBP001Member2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2030 Fund2024-01-012024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Member2023-12-310000711377Vanguard Target Retirement 2020 Fundneog:EBP001Member2024-12-310000711377Vanguard Small-Cap Growth Index Fund Admiral Sharesneog:EBP001Member2024-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Member2023-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Member2024-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Member2024-12-310000711377neog:EBP001Membersrt:MaximumMember2024-01-012024-12-310000711377Vanguard Equity-Income Fund Admiral Sharesneog:EBP001Member2024-01-012024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2040 Fund2024-01-012024-12-310000711377neog:EBP001MemberAmerican Funds EuroPacific Growth Fund Class R-62024-01-012024-12-310000711377neog:EBP001Member2023-12-310000711377neog:EBP001MemberPutnam Stable Value Fund2024-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2023-12-310000711377Pioneer Strategic Income Fund Class Kneog:EBP001Member2024-01-012024-12-310000711377JPMorgan Mid Cap Value Fund Class R6neog:EBP001Member2024-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2024-12-310000711377neog:EBP001MemberLarge Cap Growth III R12024-12-310000711377Fidelity Large Cap Growth Index Fundneog:EBP001Member2024-01-012024-12-310000711377neog:EBP001Memberus-gaap:MutualFundMember2024-12-310000711377neog:EBP001Memberneog:EmployeeBenefitPlansMutualFundsAndCommonStockOfPlanSponsorMember2024-12-310000711377Fidelity Large Cap Growth Index Fundneog:EBP001Member2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2040 Fund2024-12-310000711377neog:EBP001Memberus-gaap:FairValueInputsLevel1Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2023-12-310000711377neog:EBP001Memberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2023-12-310000711377Pioneer Strategic Income Fund Class Kneog:EBP001Member2024-12-310000711377neog:EBP001MemberPutnam Stable Value Fund2024-01-012024-12-3100007113772024-01-012024-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2070 Fund2024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberus-gaap:MutualFundMember2023-12-310000711377Vanguard Small-Cap Growth Index Fund Admiral Sharesneog:EBP001Member2024-01-012024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2055 Fund2024-01-012024-12-310000711377neog:EBP001MemberFidelity Small Cap Index Fund2024-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Member2023-12-310000711377neog:EBP001Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCommonCollectiveTrustMember2024-12-310000711377us-gaap:FairValueInputsLevel3Memberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2023-12-310000711377neog:EBP001MemberVanguard Target Retirement 2070 Fund2024-01-012024-12-310000711377us-gaap:FairValueInputsLevel2Memberneog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2023-12-310000711377neog:EBP001MemberFidelity Large Cap Value Index Fund2024-01-012024-12-310000711377neog:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2023-12-310000711377neog:EBP001Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000711377neog:EBP001MemberT. Rowe Price Blue Chip Growth Fund I Class2024-12-310000711377Vanguard Target Retirement 2020 Fundneog:EBP001Member2024-01-012024-12-310000711377neog:EBP001MemberFidelity U.S. Bond Index Fund2024-12-310000711377neog:EBP001MemberVanguard Target Retirement 2060 Fund2024-01-012024-12-31iso4217:USDxbrli:sharesxbrli:purexbrli:sharesiso4217:USD

     

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549-1004

     

    FORM 11-K

     

     

     

    X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES

    EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2024

     

    OR

     

    __ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES

     

    For the transition period from _____ to _____

     

    Commission file number: 0-17988

     

     

    NEOGEN 401(k) RETIREMENT SAVINGS PLAN

    (Full title of the plan and the address of the plan, if

    different from that of the issuer named below)

     

     

    Neogen Corporation

    620 Lesher Place, Lansing, Michigan 48912

    (Name of issuer of the securities held pursuant to

    the plan and the address of its principal

    executive office)

     

     


     

     

     

     

     

     

     

     

     

     

    Audited Financial Statements

    and

    Supplemental Schedule

     

    Neogen 401(k) Retirement Savings Plan

     

    Years Ended December 31, 2024 and 2023

    with Report of Independent Registered Public Accounting Firm

     

     


     

    Table of Contents

     

     

    Report of Independent Registered Public Accounting Firm

    1

     

     

    Audited Financial Statements

     

     

    Statements of Net Assets Available for Benefits

    3

    Statement of Changes in Net Assets Available for Benefits

    4

    Notes to Financial Statements

    5

     

     

    Supplemental Schedule

     

     

     

     

    Schedule H, Part IV, Line 4i - Schedule of Assets (Held at End of Year)

    14

     

     

    SIGNATURE

    15

     

     

    EXHIBIT INDEX

     

     

     

    Exhibit 23 Consent of Independent Registered Public Accounting Firm

    16

     

     

     

     


     

    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

     

     

     

    Audit Committee of Neogen Corporation,

    the Plan Administrator, and Plan Participants

    of Neogen 401(k) Retirement Savings Plan

    Lansing, Michigan

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of the Neogen 401(k) Retirement Savings Plan(the “Plan”) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes and schedule (collectively referred to as the “financial statements”).

    In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits of the financial statements provide a reasonable basis for our opinion.

    1


     

    Supplemental Information

    The accompanying December 31, 2024 supplemental schedule of assets (held at end of year) has been subjected to audit procedures performed in conjunction with our audit of the 2024 Neogen 401(k) Retirement Savings Plan financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedules. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the United States Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

     

    /s/ Rehmann Robson LLC

    We have served as Neogen 401(k) Retirement Savings Plan’s independent auditor since 2022.

     

     

    Saginaw, Michigan

    June 24, 2025

     

     

     

     

    2


     

    Neogen 401(k) Retirement Savings Plan

     

    Statements of Net Assets Available for Benefits

    December 31, 2024 and 2023

     

     

    December 31,

     

     

    2024

     

     

    2023

     

    Assets

     

     

     

     

     

    Investments, at fair value:

     

     

     

     

     

    Mutual funds

    $

    97,002,628

     

     

    $

    87,568,889

     

    Common stock of Plan Sponsor

     

    5,203,906

     

     

     

    8,513,372

     

    Collective investment trusts

     

    4,894,309

     

     

     

    4,966,139

     

    Total Investments

     

    107,100,843

     

     

     

    101,048,400

     

     

     

     

     

     

     

    Receivables:

     

     

     

     

     

    Employee contributions

     

    53,112

     

     

     

    291,458

     

    Employer contributions

     

    25,432

     

     

     

    119,338

     

    Notes receivable from participants

     

    954,537

     

     

     

    801,413

     

    Total Receivables

     

    1,033,081

     

     

     

    1,212,209

     

     

     

     

     

     

     

    Total Assets (equal to net assets available for benefits)

    $

    108,133,924

     

     

    $

    102,260,609

     

     

    See accompanying notes to financial statements.

    3


     

    Neogen 401(k) Retirement Savings Plan

     

    Statement of Changes in Net Assets Available for Benefits

    Year Ended December 31, 2024

     

    Additions

     

     

     

    Investment income:

     

     

     

    Net appreciation in fair value of investments

     

    $

    6,770,442

     

    Interest and dividends

     

     

    3,714,678

     

     

     

     

     

    Interest income on notes receivable from participants

     

     

    73,747

     

     

     

     

     

    Contributions:

     

     

     

    Employee contributions

     

     

    8,050,520

     

    Employer contributions

     

     

    3,438,360

     

    Other contributions

     

     

    2,474,238

     

     

     

     

     

    Total contributions

     

     

    13,963,118

     

     

     

     

     

    Total additions

     

     

    24,521,985

     

     

     

     

     

    Deductions

     

     

     

    Benefits paid to participants

     

     

    18,461,779

     

    Administrative expenses

     

     

    186,891

     

     

     

     

     

    Total deductions

     

     

    18,648,670

     

     

     

     

     

    Net change in net assets available for benefits

     

     

    5,873,315

     

     

     

     

     

    Net assets available for benefits at beginning of year

     

     

    102,260,609

     

     

     

     

     

    Net assets available for benefits at end of year

     

    $

    108,133,924

     

     

    See accompanying notes to financial statements.

    4


     

    Neogen 401(k) Retirement Savings Plan

    Notes to Financial Statements

     

    1. Description of the Plan

     

    The following description of the Neogen 401(k) Retirement Savings Plan (Plan) is provided for general information purposes only. Participants should refer to the plan document for more complete information.

     

    General

     

    The Plan is a defined contribution plan covering the employees of Neogen Corporation (the “Plan Sponsor” or “Company”) who meet the age and service requirements. Management of the Company control and manage the operation and administration of the Plan. Fidelity Management Trust Company serves as the trustee of the Plan. Marsh McLennan Agency, LLC serves as the Plan’s investment advisor. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA).

     

    Contributions

     

    Each year, participants may contribute a percentage of their pretax annual compensation, as defined in the plan document. Participants may choose to contribute to a Traditional 401(k), Roth 401(k) or both, within the Plan. Participants are eligible for Company matching contributions after attaining six months of service. The Company makes matching contributions as follows: $1.00 for each $1.00 on the first 3% of participant contributions and $.50 on each $1.00 on the next 2% of participant contributions up to the maximum allowable by the IRS. Contributions are subject to certain Internal Revenue Code (IRC) limitations. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans.

     

    Vesting

     

    Participants are vested immediately in their contributions plus actual earnings thereon. Participants are immediately vested in the Company contribution portion of their account.

    5


     

     

    Forfeitures

     

    Forfeitures of non-vested performance contributions are used to reduce future employer contributions or pay administrative expenses of the Plan. At December 31, 2024, forfeited non-vested accounts total $129. At December 31, 2023, forfeited non-vested accounts total $75. No forfeited nonvested accounts were utilized in 2024 or 2023.

     

    Participants’ Accounts

     

    Individual accounts are maintained for each Plan participant. Each participant’s account is credited with the participant’s contribution, the Company’s matching contribution, and allocations of Plan earnings, and charged with an allocation of Plan earnings and administrative expenses. Allocations are based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.

     

    Investments

     

    Participants direct the investment of their contributions into various investment options offered by the Plan. Company contributions are automatically invested and subject to the same allocation percentages as the participant contributions. The Plan currently offers a variety of mutual funds, common stock of the Company, and a selection of collective investment trust options.

     

    Notes Receivable from Participants

     

    Participants may borrow from their fund accounts up to a maximum amount equal to the lesser of $50,000 or 50% of the present value of their account balance. Loan transactions are treated as a transfer to (from) the investment fund from (to) the participant’s loan fund. The loans are secured by the balances in the participants’ accounts and bear interest at a rate commensurate with prevailing interest rates charged by persons in the business of lending money for loans which would be made under similar circumstances. The interest rate on new loans is prime plus one percent at time of origination and shall remain fixed throughout the duration of the loan unless a change is required by applicable law for any participant(s) taking a military leave of absence. Principal and interest are paid ratably through payroll deductions.

     

    Payment of Benefits

     

    On termination of service due to death, normal, early or disability retirement, or other termination of employment, a participant may elect to receive either: (a) lump-sum amount equal to the value of the participant’s vested balance in his or her account; or (b) partial withdrawals for those that meet certain Plan provisions.

    6


     

     

    2. Summary of Significant Accounting Policies

     

    Basis of Accounting

     

    The accompanying financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).

     

    Investment Valuation and Income Recognition

     

    The Plan’s mutual fund and common stock investments are stated at fair value as of the end of the Plan year based on the quoted market prices of the underlying assets. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. The Plan’s interests in the collective investment trusts are based on the fair value of each fund’s underlying investments as reported by the fund’s portfolio manager using the audited financial statements of the fund at year-end.

     

    Fair Value Measurements

     

    As defined in the current authoritative guidance, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance applies to all financial instruments that are measured and reported on a fair value basis. The Plan utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of inputs used in the valuation techniques the Plan is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:

     

    •
    Level 1 – Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date.

    •
    Level 2 – Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

     

    •
    Level 3 – Significant unobservable inputs that reflect a company’s own assumptions about the assumptions that market participants would use in pricing an asset or liability.

     

    For the years ended December 31, 2024 and 2023, the application of valuation techniques applied to similar assets and liabilities has been consistent.

     

    7


     

    Notes Receivable from Participants

     

    Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Loans in default are reclassified as benefit payments to participants based upon the terms of the Plan document.

     

    Contributions

     

    Contributions from participants are recorded when withheld from compensation. Contributions from the Company are recorded in the period in which they become obligations of the Company.

     

    Expenses

     

    Plan administrative expenses may be paid by either the Plan or the Company, as provided in the Plan document.

     

    Payments of Benefits

     

    Benefit payments to participants are recorded as deductions from the Plan upon distribution.

     

    Excess Contributions Payable

     

    The Plan is required to return contributions received during the Plan year in excess of IRC limits. Amounts payable to participants for contributions in excess of amounts allowed by the Internal Revenue Service, if any, are recorded as a liability with a corresponding reduction to contributions.

     

    Use of Estimates

     

    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of net assets available for benefits and changes therein. Actual results could differ from those estimates. The Plan utilizes various investment valuation techniques. Investment securities, in general, are exposed to various risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

     

    3. Plan Termination

     

    Although it has not expressed any intention to do so, the Company has the right, under the Plan, to discontinue its contributions at any time and to terminate the Plan subject to the provisions set forth in ERISA. In the event the Plan is terminated, participants would become 100% vested in their accounts.

     

    8


     

    4. Fair Value Measurements

     

    The following is a description of the valuation methodologies used for assets measured at fair value.

     

    Mutual funds:

    Valued at the net asset value of shares held by the Plan at year end. Mutual funds held by the Plan are open-ended mutual funds that are registered with the SEC. These funds are required to publish their daily net asset value and transact at that price and therefore are deemed to be actively traded.

    Common stock of Plan Sponsor:

    Valued at the year-end closing price reported on the active market on which the security is traded.

    Collective Investment Trusts:

    Valued at net asset value as a practical expedient to estimate fair value at year end.

     

    The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

     

    The following tables set forth by level, within the fair value hierarchy, the Plan’s assets at fair value as of December 31, 2024 and 2023.

     

     

     

    Assets at Fair Value as of December 31, 2024

     

     

     

    Level 1

     

     

    Level 2

     

     

    Level 3

     

     

    Total

     

    Assets

     

     

     

     

     

     

     

     

     

     

     

     

    Mutual funds

     

    $

    97,002,628

     

     

    $

    -

     

     

    $

    -

     

     

    $

    97,002,628

     

    Common stock of Plan Sponsor

     

     

    5,203,906

     

     

     

    -

     

     

     

    -

     

     

     

    5,203,906

     

    Total assets in the fair value hierarchy

     

     

    102,206,534

     

     

     

    -

     

     

     

    -

     

     

     

    102,206,534

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Investments measured at net asset value

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    4,894,309

     

    Total investments, at fair value

     

    $

    102,206,534

     

     

    $

    -

     

     

    $

    -

     

     

    $

    107,100,843

     

     

     

     

     

    Assets at Fair Value as of December 31, 2023

     

     

     

    Level 1

     

     

    Level 2

     

     

    Level 3

     

     

    Total

     

    Assets

     

     

     

     

     

     

     

     

     

     

     

     

    Mutual funds

     

    $

    87,568,889

     

     

    $

    -

     

     

    $

    -

     

     

    $

    87,568,889

     

    Common stock of Plan Sponsor

     

     

    8,513,372

     

     

     

    -

     

     

     

    -

     

     

     

    8,513,372

     

    Total assets in the fair value hierarchy

     

     

    96,082,261

     

     

     

    -

     

     

     

    -

     

     

     

    96,082,261

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Investment measured at net asset value

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    4,966,139

     

    Total investments, at fair value

     

    $

    96,082,261

     

     

    $

    -

     

     

    $

    -

     

     

    $

    101,048,400

     

     

    9


     

     

    The following tables summarize investments for which fair value is measured using the net asset value per share practical expedient as of December 31, 2024 and 2023. There are no participant redemption restrictions for these investments; the redemption notice period is applicable only to the Plan.

     

     

     

     

     

     

     

     

    Redemption

     

     

     

     

     

     

     

     

     

    Frequency (If

     

     

    December 31,

     

     

     

     

    Unfunded

     

    Currently

     

    Redemption

    2024

     

    Fair Value

     

     

    Commitments

     

    Eligible)

     

    Notice Period

    Collective trust funds

     

    $

    4,894,309

     

     

    n/a

     

    Daily

     

    12 months

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Redemption

     

     

     

     

     

     

     

     

     

    Frequency (If

     

     

    December 31,

     

     

     

     

    Unfunded

     

    Currently

     

    Redemption

    2023

     

    Fair Value

     

     

    Commitments

     

    Eligible)

     

    Notice Period

    Collective trust fund

     

    $

    4,966,139

     

     

    n/a

     

    Daily

     

    12 months

     

    5. Parties-In-Interest

     

    Certain Plan investments are managed by Fidelity Management Trust Company. Fidelity Management Trust Company is the custodian and trustee of the Plan and, therefore, transactions with Fidelity Management Trust Company qualify as party-in-interest transactions. Fees paid by the Plan for the custodial, advisory, and record keeping services amounted to $186,891 for 2024. Fees paid by the Plan for investment management, auditing and other professional services rendered by parties-in-interest were based on customary and reasonable rates for such services.

     

    The Plan invests in the common stock of Neogen Corporation, the Plan’s Sponsor, a party-in-interest. Investment in Neogen Corporation common stock was $5,203,906 and $8,513,372 as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the investment in Neogen Corporation’s common stock represents 428,658 shares at a market price of $12.14 per share. As of December 31, 2023, the investment in Neogen Corporation’s common stock represents 423,340 shares at a market price of $20.11 per share.

     

    10


     

    6. Risks and Uncertainties

     

    The Plan invests in common stock of the Plan Sponsor, mutual funds, and common collective trusts with underlying assets consisting of any combination of stocks, bonds, fixed income securities and other investment securities. Investment securities are exposed to various risks, such as interest rate, market, and credit risks. Market risks include global events which could impact the value of investment securities, such as a pandemic or international conflict. Due to the level of interest rate, market, and credit risks inherent with certain of the Plans investment securities, it is at least reasonably possible that changes in the fair values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits and changes in net assets available for benefits.

     

    7. Federal Income Tax Status

     

    The Plan is maintained through the adoption of a pre-approved plan that has received an opinion letter from the IRS dated June 30, 2020, stating that the form of the plan is qualified under Section 401(a) of the Code and therefore, the related trust is tax-exempt. The Plan administrator has determined that it is eligible to, and chose to, rely on the current IRS opinion letter with respect to the qualified status of the Plan. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualified status. The Plan administrator believes the Plan is being operated in compliance with the applicable requirements of the Code and, therefore, believes the Plan is qualified and the related trust is tax-exempt.

     

    U.S. GAAP requires Plan management to evaluate and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. While the Plan may be subject to routine audits of taxing jurisdictions, there are currently no audits for any tax periods in progress.

    

    8. Reconciliation of Financial Statements to Form 5500

     

    The following is a reconciliation of net assets available for benefits per the financial statements to IRS Form 5500 as of December 31, 2024 and 2023:

     

     

    December 31,

     

     

    2024

     

     

    2023

     

    Net assets available for benefits per the financial statements

    $

    108,133,924

     

     

    $

    102,260,609

     

    Deemed distributions reported on 5500

     

    (47,387

    )

     

     

    (24,332

    )

    Net assets available for benefits per the Form 5500

    $

    108,086,537

     

     

    $

    102,236,277

     

     

    Deemed distributions are defaulted and unpaid participant loans of active participants that are reflected as distributions on the Form 5500 and as notes receivable from participants on the financial statements. Upon a distributable event, the deemed distributions will be reflected as distributions in the financial statements.

     

    11


     

    The following is a reconciliation of changes in net assets available for plan benefits per the financial statements to the Form 5500 for the year ended December 31, 2024:

     

    Increase in net assets available for benefits per the financial statements

    $

    5,873,315

     

    Change in deemed distributions

     

    (23,055

    )

    Net income per Form 5500

    $

    5,850,260

     

     

    9. Subsequent Events

     

    In preparing the Plan’s financial statements, subsequent events and transactions have been evaluated for potential recognition or disclosure. Plan management determined that there are no subsequent events or transactions that require disclosure to or adjustment in the financial statements through the filing date of this Form 11-K.

     

    12


     

    Supplemental Schedule

    13


     

    Neogen 401(k) Retirement Savings Plan

    Schedule H, Part IV, Line 4i - Schedule of Assets (Held at End of Year)

    As of December 31, 2024

     

     

     

     

     

     

     

     

    (a)

    (b) Identity of Issue, Borrower, Lessor, or Similar Party

     

    (c) Description of investment including maturity date, rate of interest, collateral, par, or maturity value

    (d) Cost

     

    (e) Current Value

     

     

    *

    Fidelity U.S. Bond Index Fund

     

    Mutual Fund

     

    N/A

    $

    459,134

     

     

    *

    Fidelity 500 Index Fund

     

    Mutual Fund

     

    N/A

     

    16,708,488

     

     

    *

    Fidelity Mid Cap Index Fund

     

    Mutual Fund

     

    N/A

     

    2,726,061

     

     

    *

    Fidelity Small Cap Index Fund

     

    Mutual Fund

     

    N/A

     

    1,357,066

     

     

    *

    Fidelity International Index Fund

     

    Mutual Fund

     

    N/A

     

    2,643,315

     

     

    *

    Fidelity Large Cap Growth Index Fund

     

    Mutual Fund

     

    N/A

     

    4,301,549

     

     

    *

    Fidelity Large Cap Value Index Fund

     

    Mutual Fund

     

    N/A

     

    970,404

     

     

    *

    Fidelity Government Money Market Fund

     

    Mutual Fund

     

    N/A

     

    18,915

     

     

     

    Large Cap Growth III R1

     

    Collective Investment Trust

     

    N/A

     

    873,744

     

     

     

    Vanguard Target Retirement 2055 Fund

     

    Mutual Fund

     

    N/A

     

    5,699,835

     

     

     

    Blackrock Mid Cap Growth Equity Portfolio

     

    Mutual Fund

     

    N/A

     

    2,223,326

     

     

     

    Vanguard Target Retirement 2065 Fund

     

    Mutual Fund

     

    N/A

     

    1,366,503

     

     

     

    T. Rowe Price Blue Chip Growth Fund I Class

     

    Mutual Fund

     

    N/A

     

    6,526,817

     

     

     

    JPMorgan Mid Cap Value Fund Class R6

     

    Mutual Fund

     

    N/A

     

    1,894,905

     

     

     

    Vanguard Target Retirement 2020 Fund

     

    Mutual Fund

     

    N/A

     

    87,870

     

     

     

    Vanguard Target Retirement 2030 Fund

     

    Mutual Fund

     

    N/A

     

    2,634,937

     

     

     

    Vanguard Target Retirement 2040 Fund

     

    Mutual Fund

     

    N/A

     

    1,517,662

     

     

     

    Vanguard Target Retirement 2050 Fund

     

    Mutual Fund

     

    N/A

     

    2,534,715

     

     

     

    Baird Core Plus Bond Fund Class Institutional

     

    Mutual Fund

     

    N/A

     

    2,585,122

     

     

     

    Vanguard Target Retirement 2070 Fund

     

    Mutual Fund

     

    N/A

     

    1,501

     

     

     

    Vanguard Equity-Income Fund Admiral Shares

     

    Mutual Fund

     

    N/A

     

    2,827,871

     

     

     

    Vanguard Explorer Fund Admiral Shares

     

    Mutual Fund

     

    N/A

     

    2,609,924

     

     

     

    Vanguard Target Retirement Income Fund Investor Shares

     

    Mutual Fund

     

    N/A

     

    533,669

     

     

     

    Vanguard Target Retirement 2025 Fund

     

    Mutual Fund

     

    N/A

     

    5,315,892

     

     

     

    Vanguard Target Retirement 2035 Fund

     

    Mutual Fund

     

    N/A

     

    8,247,188

     

     

     

    Vanguard Target Retirement 2045 Fund

     

    Mutual Fund

     

    N/A

     

    11,823,595

     

     

     

    Vanguard Inflation-Protected Securities Fund Admiral Shares

     

    Mutual Fund

     

    N/A

     

    529,369

     

     

     

    Pioneer Strategic Income Fund Class K

     

    Mutual Fund

     

    N/A

     

    465,419

     

     

     

    American Funds EuroPacific Growth Fund Class R-6

     

    Mutual Fund

     

    N/A

     

    4,545,978

     

     

     

    American Funds American Balanced Fund Class R-6

     

    Mutual Fund

     

    N/A

     

    1,706,338

     

     

     

    Allspring Special Small Cap Value Fund - Class R6

     

    Mutual Fund

     

    N/A

     

    667,225

     

     

     

    Vanguard Target Retirement 2060 Fund

     

    Mutual Fund

     

    N/A

     

    1,242,648

     

     

     

    Vanguard Small-Cap Growth Index Fund Admiral Shares

     

    Mutual Fund

     

    N/A

     

    229,387

     

     

     

    Putnam Stable Value Fund

     

    Collective Investment Trust

     

    N/A

     

    4,020,565

     

     

     

     

     

     

     

     

     

     

    -

     

     

     

    Common Stock—

     

     

     

     

     

     

     

    *

    Neogen Corporation

    Common Stock

     

    N/A

     

    5,203,906

     

     

     

    Investments at fair value

     

     

     

    $

    107,100,843

     

     

    *

    Notes receivable from participants

    Interest rates of 4.25% to 9.50%, maturing through 2029

     

     

    954,537

     

     

     

    TOTAL

     

     

    $

    108,055,380

     

     

     

    * Party-in-interest

     

     

     

     

     

     

     

     

     

    N/A Not applicable—Cost information is not required with respect to participant or beneficiary directed transactions under an individual account plan.

     

    Employer Identification Number 38-2367843

     

     

     

     

     

     

     

     

     

    Three Digit Plan Number: 001

     

     

     

     

     

     

     

     

     

    14


     

     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

     

     

     

     

     

     

    NEOGEN 401(K) RETIREMENT SAVINGS PLAN

                         (Registrant)

     

     

     

     

    Dated: June 24, 2025

     

    By:

     

    /s/ John Moylan

     

     

     

    John Moylan

     

     

     

    Plan Administrator

     

    15


     

    EXHIBIT INDEX

     

     

    Exhibit No. Description

     

    Exhibit 23 Consent of Independent Registered Public Accounting Firm

     

    16


    Get the next $NEOG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wainer Andrea F was granted 6,090 shares (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      6/4/25 4:08:39 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Wainer Andrea F

      3 - NEOGEN CORP (0000711377) (Issuer)

      6/4/25 4:01:51 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer Naemura David H. was granted 52,724 shares, increasing direct ownership by 86% to 114,158 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      6/4/25 12:54:50 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neogen Announces Fourth-Quarter Earnings Release Date

      Neogen® Corporation (NASDAQ:NEOG) will issue its fourth-quarter earnings release before the opening of the market on Tuesday, July 29, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 65461 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusio

      7/8/25 4:05:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Launches Second Edition Environmental Monitoring Handbook to Elevate Food Safety Practices

      Industry-leading resource developed with Cornell University's College of Agriculture and Life Sciences (CALS) and 20+ global experts provides a framework for building and enhancing environmental monitoring programs In recognition of World Food Safety Day, Neogen® Corporation (NASDAQ:NEOG) today announced the release of the Second Edition Neogen Environmental Monitoring Handbook, a comprehensive resource designed to help food and beverage manufacturers strengthen food safety programs and reduce contamination risks. The updated guide introduces critical new insights on validating risk-based controls, conducting root cause analysis, and leveraging data for continuous improvement, providing f

      6/5/25 8:30:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® to Participate in the 45th Annual William Blair Growth Stock Conference

      Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that the Company will participate in the 45th Annual William Blair Growth Stock Conference in Chicago, Illinois, on Wednesday, June 4, 2025. David Naemura, Neogen's Chief Financial Officer and Chief Operating Officer, will present at 8:40 a.m. Central Time. To access the event webcast link, please visit the Events & Presentations section at neogen.com/investor-relations/events-presentations. About Neogen Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology,

      5/21/25 9:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    SEC Filings

    See more
    • SEC Form 11-K filed by Neogen Corporation

      11-K - NEOGEN CORP (0000711377) (Filer)

      6/24/25 3:41:28 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      6/4/25 8:59:08 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SD filed by Neogen Corporation

      SD - NEOGEN CORP (0000711377) (Filer)

      5/29/25 9:26:37 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gupta Aashima bought $99,987 worth of shares (16,000 units at $6.25), increasing direct ownership by 270% to 21,917 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      5/12/25 2:30:47 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 4:32:35 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Borel James C bought $149,700 worth of shares (30,000 units at $4.99), increasing direct ownership by 50% to 90,474 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 2:45:19 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Neogen with a new price target

      Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

      12/19/24 8:18:19 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Wells Fargo initiated coverage on Neogen with a new price target

      Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

      6/16/23 7:34:39 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen upgraded by William Blair

      William Blair upgraded Neogen from Mkt Perform to Outperform

      11/22/22 8:02:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Financials

    Live finance-specific insights

    See more
    • Neogen Announces Fourth-Quarter Earnings Release Date

      Neogen® Corporation (NASDAQ:NEOG) will issue its fourth-quarter earnings release before the opening of the market on Tuesday, July 29, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 65461 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusio

      7/8/25 4:05:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter 2025 Results

      Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

      4/9/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter Earnings Release Date

      LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing:Toll-Free - North America: 1-800-549-8228International: (+1) 646-564-2877Conference ID: 63045 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/inves

      3/20/25 4:15:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    See more
    • Neogen® Announces CEO Transition

      Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

      4/9/25 7:01:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Neogen Announces the Appointment of New Board Member

      LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

      10/1/24 8:45:00 AM ET
      $NEOG
      $QGEN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neogen Corporation

      SC 13G - NEOGEN CORP (0000711377) (Subject)

      11/14/24 4:28:12 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Neogen Corporation

      SC 13G - NEOGEN CORP (0000711377) (Subject)

      11/14/24 11:16:20 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/13/24 5:09:41 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care